FDA Expands Marstacimab Indication in Hemophilia A and B - Top_Thought_Leaders - MDSpire

FDA Expands Marstacimab Indication in Hemophilia A and B

  • By

  • Kathryn Wighton

  • June 8, 2026

Share

Top Thought Leaders in Endocrinology

Brief introduction explaining scope and methodology.

Original Source(s)

FDA Expands Marstacimab Indication in Hemophilia A and B

  • by Kathryn Wighton

  • June 8, 2026

Related Content

Social connectedness in mobile gaming: how family dynamics shape children’s virtual interactions

Correction: Measuring mental wellbeing in children aged 5 to 12 years: validation of the COMPAS-KIDS and COMPAS-PARENTS mental wellbeing scales in the general community

Explainable machine learning unveils the key role of cooperation ability in school bullying and its gender-differentiated impact on cooperative atmosphere